Company Directory - Gilead Sciences, Inc.
Company Details - Gilead Sciences, Inc.
Gilead Sciences, Inc.
WebsiteFoster City, USA
ISIN: US3755581034
Gilead Sciences, Inc. is a research‐based biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for unmet medical needs. The company is known for its contributions to antiviral treatments, including therapies for HIV and, more recently, the development of lenacapavir for HIV prevention.
CCI Score
CCI Score: Gilead Sciences, Inc.
1.64
-0.01%
Latest Event
Gilead Sciences Lobbying and Revolving Door Influence
The OpenSecrets profile reveals that Gilead Sciences spent $8,760,000 on lobbying in the 2024 cycle and contributed $882,271, while a significant portion of its lobbyists have prior government experience, raising concerns over undue corporate and political influence.
Take Action
So what can you do? Support Gilead by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
OBJECTOR
Gilead Sciences, Inc. is currently rated as an Objector.
Latest Events
- FEB192025
The OpenSecrets profile reveals that Gilead Sciences spent $8,760,000 on lobbying in the 2024 cycle and contributed $882,271, while a significant portion of its lobbyists have prior government experience, raising concerns over undue corporate and political influence.
-40
Political Contributions and Lobbying Efforts
April 3
Gilead Sciences' profile on OpenSecrets shows substantial lobbying expenditures ($8,760,000) and notable campaign contributions ($882,271) during the 2024 cycle. Such financial influence can undermine democratic processes and favor corporate interests, aligning with concerns over authoritarian influence.
-30
Executive Political Engagement
April 3
The profile indicates a high degree of revolving door activity, with a significant number of Gilead Sciences’ lobbyists having previously held government positions. This close connection between corporate lobbying and government roles raises serious concerns about conflicts of interest and potential authoritarian influence.
- JAN232025
Gilead Sciences, Inc. has been reported to have contributed approximately $882,271 and spent about $8,760,000 on lobbying in the 2024 cycle, indicating significant efforts to shape policy. From a left-leaning perspective, such sizable lobbying expenditures raise concerns about the undue influence over political processes that may indirectly support authoritarian practices.
-40
Political Contributions and Lobbying Efforts
March 18
The data from OpenSecrets reveals that Gilead Sciences spent $8.76 million on lobbying activities in the 2024 cycle, which is significantly high relative to its political contributions of $882,271. This disproportionate focus on lobbying suggests a strategic effort to influence political processes in a manner that could support policies favoring corporate interests over public welfare. Such actions are viewed negatively from an anti-fascist perspective as they may contribute to the erosion of democratic accountability and enable undue corporate influence in politics.
- JAN012025
Gilead Sciences, Inc. has published an archive detailing its political contributions to state and local candidates and political organizations. From a left‐leaning perspective, such transparency in political funding also underscores corporate influence on public policy, which can facilitate environments ripe for undermining democratic accountability when aligned with authoritarian agendas.
-30
Political Contributions and Lobbying Efforts
March 18
The archived political contributions reveal that Gilead Sciences is actively involved in funding political entities. While transparency is provided, from an anti-fascist lens, corporate financial involvement in politics can exert undue influence over democratic processes and potentially support policies aligned with authoritarian interests. This rating reflects concerns over the broader societal impact of corporate political contributions in a climate where such funding can erode public accountability.
- DEC312024
Gilead Sciences, Inc. spent $2.44M on lobbying activities in Q4 2024, focusing on issues such as drug pricing, intellectual property protection, and pharmaceutical regulatory reforms. This level of corporate lobbying raises concerns from an anti-fascist perspective as it seeks to influence policy in ways that may prioritize corporate profits over public welfare and democratic accountability.
-60
Political Contributions and Lobbying Efforts
January 22
The disclosed $2.44M lobbying expenditure by Gilead Sciences, Inc. in Q4 2024 reveals significant investment in influencing legislative and regulatory issues such as drug pricing, intellectual property, and healthcare reforms. From an anti-fascist, left-leaning perspective, this substantial use of resources to shape public policy is seen as prioritizing corporate interests over public good, potentially undermining democratic processes and supporting structures that align with authoritarian economic practices.
Lobbying Update: $2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed
- DEC312024
Gilead Sciences, Inc. spent $8.76M on lobbying in 2024, raising concerns about its political influence and potential complicity in supporting policies that favor authoritarian practices.
-50
Political Contributions and Lobbying Efforts
March 18
Gilead Sciences' reported expenditure of $8.76M on lobbying in 2024 suggests significant investment in influencing political processes. From an anti-fascist perspective, such heavy lobbying spending can be seen as attempting to shape policy environments in ways that may inadvertently support authoritarian practices and undermine democratic accountability.
- DEC162024
Shareholders urge Gilead Sciences to adopt a comprehensive human rights policy that covers its own operations in addition to its suppliers. Critics point out that while Gilead maintains a supplier code of conduct, it neglects to perform rigorous human rights due diligence (HRDD) within its own operations, contributing to limited access to essential HIV treatments and other therapeutic drugs.
-50
Labor Relations and Human Rights Practices
March 18
Gilead Sciences has been criticized for not implementing a comprehensive human rights policy that applies to its own operations. Despite having a supplier code of conduct, the lack of an inclusive HRDD process exposes gaps in respecting international human rights and the right to health, especially given its controversial pricing and limited access to lifesaving HIV medications.
-40
Supply Chain Ethics
March 18
The company's reliance on a supplier code of conduct that excludes mandatory human rights due diligence for its own operations indicates significant ethical oversights in its supply chain management. This approach potentially masks broader risks and adverse impacts on patients' access to essential medications.
- DEC162024
Shareholders of Gilead Sciences have formally urged the board to adopt a comprehensive human rights policy that commits the company to respecting internationally recognized human rights, including the right to health, and to implement human rights due diligence (HRDD). The call comes amid longstanding criticisms of the company’s drug access policies, including limited access to lifesaving HIV medications and contentious licensing deals.
-65
Labor Relations and Human Rights Practices
April 3
The article details a shareholder resolution that criticizes Gilead Sciences for not having a comprehensive human rights policy, thereby overlooking its responsibility to ensure access to essential medicines and implement robust human rights due diligence. This failure reflects a disregard for fundamental human rights and the right to health, which is central to labor relations and ethical business practices.
- JUL092024
Gilead Sciences Pty Ltd released its Modern Slavery Statement 2023, outlining a comprehensive set of measures to assess and address modern slavery risks in its operations and supply chain. The document details updated Supplier Code of Conduct requirements, rigorous supplier due diligence, regular audits, training on modern slavery for key personnel, and contractual clauses to ensure suppliers uphold human and labor rights.
+60
Labor Relations and Human Rights Practices
April 3
Gilead's statement emphasizes strong labor practices by instituting a Code of Ethics and requiring its personnel and suppliers to uphold human rights. The measures, including training and internal audits to detect forced labor and ensure fair treatment, contribute positively to labor relations and human rights practices.
PDF (made under the Modern Slavery Act 2018 (Cth)) - gilead.com.au
+70
Supply Chain Ethics
April 3
The statement details robust supply chain ethics initiatives, including a stringent Supplier Code of Conduct, mandatory compliance with anti-slavery measures, and due diligence processes on suppliers. These efforts significantly reduce the risk of modern slavery within Gilead's extensive supplier network.
PDF (made under the Modern Slavery Act 2018 (Cth)) - gilead.com.au
- JUN252024
Gilead released a comprehensive modern slavery statement, in compliance with UK and California regulations, outlining revised supplier codes of conduct, enhanced supplier audits, and training programs to prevent forced labour and human trafficking in its supply chain.
+80
Labor Relations and Human Rights Practices
April 3
Gilead has demonstrated a strong commitment to protecting labor rights by issuing a detailed modern slavery statement, reinforcing its Code of Ethics, and implementing robust recruitment and audit processes to ensure workers' rights are upheld.
+75
Supply Chain Ethics
April 3
The updated Supplier Code of Conduct and the implementation of routine supplier audits underscore Gilead's proactive efforts to ensure ethical sourcing and to mitigate risks of forced labor and human trafficking in its global supply chain.
- JUN252024
Gilead Sciences released its Modern Slavery Statement outlining its robust commitments to labor rights and ethical supply chain practices, mitigating risks of forced labor and human trafficking within its operations and supplier network.
+80
Labor Relations and Human Rights Practices
March 18
Gilead demonstrates strong labor relations and human rights practices through its comprehensive modern slavery statement, internal codes of ethics, and robust training and audit programs. The company clearly outlines measures to prevent forced labor in its own operations, reflecting a commitment to upholding high standards in worker treatment.
+75
Supply Chain Ethics
March 18
Gilead’s proactive supplier code of conduct, regular supplier audits, and adherence to international standards in its supply chain demonstrate its commitment to ethical sourcing and transparency. These measures reduce the risk of forced labor and modern slavery in its global supply chain.
- JUN252024
In 2023, Gilead Sciences completed supplier site assessment audits using Pharmaceutical Supply Chain Initiative (PSCI) resources and revised its Supplier Code of Conduct to enhance compliance with modern slavery laws, reflecting a strong commitment to labor rights and ethical sourcing.
+80
Labor Relations and Human Rights Practices
April 3
Gilead’s proactive audits and measures to address modern slavery risks within its workforce and supply chains demonstrate a strong commitment to labor rights and human rights practices, helping to protect vulnerable workers from exploitation.
+75
Supply Chain Ethics
April 3
By instituting routine supplier audits and updating its Supplier Code of Conduct to incorporate PSCI principles, Gilead demonstrates a commitment to ethical business practices in its supply chain, reducing risks of forced labor and modern slavery.
- JUN012024
In its June 2024 disclosure, Gilead Sciences detailed revisions to its Supplier Code of Conduct, enhanced supplier audits, and comprehensive training programs aimed at mitigating modern slavery and human trafficking risks in its supply chains.
+75
Supply Chain Ethics
April 3
Gilead's updated Supplier Code of Conduct, as disclosed in its modern slavery compliance statement, demonstrates a significant commitment to ethical supply chain management and human rights. The revisions and robust audit practices serve to reduce risks of forced labor and human trafficking, aligning with progressive, anti-fascist values by prioritizing worker and community protection.
PDF Gilead Statement of Disclosure and Compliance with Section 54 of the ...
- JAN012024
Gilead Sciences detailed its rigorous and transparent process for political contributions. The company outlines its internal review and compliance procedures—led by its Senior Vice President of Government Affairs and Policy—to ensure that contributions support public health policy and scientific innovation while adhering to legal requirements.
+30
Political Contributions and Lobbying Efforts
April 3
Gilead’s approach to political contributions involves multiple layers of review and transparency, including vetting by both internal and external compliance processes. This reduces the risk of funds being used to support authoritarian or far-right interests and promotes public health and innovation.
+20
Executive Political Engagement
April 3
The involvement of the Senior Vice President of Government Affairs and Policy in reviewing and approving contributions underscores strong executive oversight, ensuring that political spending aligns with company principles and democratic values.
- JAN012024
Gilead Sciences' public policy engagement reflects its structured and transparent approach to political contributions. The company outlines detailed internal and external compliance reviews for contributions via the Gilead PAC and corporate channels, emphasizing support for public health policy and scientific innovation. This transparent process, while still involving corporate political expenditures, is designed to mitigate reputational risk and potential abuses of political influence.
+10
Political Contributions and Lobbying Efforts
March 18
Gilead Sciences employs rigorous vetting procedures for its political contributions through both its Healthcare Policy PAC and corporate channels. While the act of engaging in political contributions inherently raises concerns about corporate influence on democratic processes, the company’s emphasis on transparency, adherence to both internal and external compliance reviews, and focus on advancing public health policy and scientific innovation mitigate some of those risks. From an anti-fascist perspective, although corporate political expenditures are generally viewed with skepticism, Gilead’s process shows a commitment to ethical political engagement, earning a moderately positive score.
- JAN012023
Gilead Sciences released a PDF document detailing its 2023 Healthcare Policy Political Action Committee (PAC) contributions. The document lists donations totaling $249,000 to various Congressional candidate committees, with several contributions directed toward Republican candidates who have been associated with authoritarian or far‐right policy positions. This disclosure raises concerns about corporate political spending that may indirectly support policies undermining progressive and workers’ interests.
-50
Political Contributions and Lobbying Efforts
April 3
The disclosed PAC contributions include significant donations to Republican candidates renowned for supporting policies that may favor authoritarian, far‐right interests. While the transparency of the disclosure is positive in principle, the allocation of funds toward political actors whose agendas can undermine progressive policies and worker rights results in a negative evaluation within the realm of political contributions and lobbying efforts.
- JAN012023
Gilead Sciences’ official website features an archive of its political contributions for 2023, providing public disclosure regarding donations to state and local candidates and political organizations. This archival page offers transparency into the company’s public and political behavior.
+10
Political Contributions and Lobbying Efforts
April 3
The availability of a publicly accessible archive of political contributions indicates a commitment to transparency in political engagement. While the archive itself does not reveal whether contributions support authoritarian or far‐right activities, the act of disclosing such donations enables public oversight and accountability. From an anti‐fascist standpoint, transparency is a positive practice that helps voters assess whether corporate political spending aligns with progressive values.
Alternatives
Thousand Oaks, USA
13.63
Corporation
0.00
Corporation
0.00
Kenilworth, United States
12.75
Corporation
11.88
Corporation
0.00
Raleigh, USA
56.52
Belgium (Ghent), Belgium
79.03
Bagsværd, Denmark
18.81
Brentford, United Kingdom
18.03
Corporate Financials
- Revenue
- 2024
- $27.70B
- Total Assets
- 2024
- $56.10B
- Operating Income
- 2024
- $5.23B
- Total Equity
- 2024
- $14.50B
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 423450
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 621511
- Medical Laboratories